title: Mitochondrial targeted catalase suppresses invasive breast cancer in mice.
abstract: BACKGROUND
  Treatment of invasive breast cancer has an alarmingly high rate of failure because effective targets have not been identified. One potential target is mitochondrial generated reactive oxygen species (ROS) because ROS production has been associated with changes in substrate metabolism and lower concentration of anti-oxidant enzymes in tumor and stromal cells and increased metastatic potential.
  
  
  METHODS
  Transgenic mice expressing a human catalase gene (mCAT) were crossed with MMTV-PyMT transgenic mice that develop metastatic breast cancer. All mice (33 mCAT positive and 23 mCAT negative) were terminated at 110 days of age, when tumors were well advanced. Tumors were histologically assessed for invasiveness, proliferation and metastatic foci in the lungs. ROS levels and activation status of p38 MAPK were determined.
  
  
  RESULTS
  PyMT mice expressing mCAT had a 12.5 per cent incidence of high histological grade primary tumor invasiveness compared to a 62.5 per cent incidence in PyMT mice without mCAT. The histological grade correlated with incidence of metastasis with 56 per cent of PyMT mice positive for mCAT showing evidence of pulmonary metastasis compared to 85.4 per cent of PyMT mice negative for mCAT with pulmonary metastasis (p ≤ 0.05). PyMT tumor cells expressing mCAT had lower ROS levels and were more resistant to hydrogen peroxide-induced oxidative stress than wild type tumor cells, suggesting that mCAT has the potential of quenching intracellular ROS and subsequent invasive behavior. The metastatic tumor burden in PyMT mice expressing mCAT was 0.1 mm2/cm2 of lung tissue compared with 1.3 mm2/cm2 of lung tissue in PyMT mice expressing the wild type allele (p ≤ 0.01), indicating that mCAT could play a role in mitigating metastatic tumor progression at a distant organ site. Expression of mCAT in the lungs increased resistance to hydrogen peroxide-induced oxidative stress that was associated with decreased activation of p38MAPK suggesting ROS signaling is dependent on p38MAPK for at least some of its downstream effects.
  
  
  CONCLUSIONS
  Targeting catalase within mitochondria of tumor cells and tumor stromal cells suppresses ROS-driven tumor progression and metastasis. Therefore, increasing the antioxidant capacity of the mitochondrial compartment could be a rational therapeutic approach for invasive breast cancer.
authors: Department of Comparative Medicine University of Washington, Seattle, USA.
authors: Jorming
authors: J
authors: Goh
authors: Linda
authors: L
authors: Enns
authors: Soroosh
authors: S
authors: Fatemie
authors: Heather
authors: H
authors: Hopkins
authors: John
authors: J
authors: Morton
authors: Christina
authors: C
authors: Pettan-Brewer
authors: Warren
authors: W
authors: Ladiges
references: Science. 2008 May 2;320(5876):661-4
references: 18388260
references: J Leukoc Biol. 2008 Sep;84(3):623-30
references: 18467655
references: Cancer Metastasis Rev. 2006 Dec;25(4):695-705
references: 17160708
references: Mol Cell. 2002 May;9(5):1031-44
references: 12049739
references: Trends Cell Biol. 2008 Apr;18(4):165-73
references: 18296052
references: Cancer Res. 2009 Mar 15;69(6):2375-83
references: 19276362
references: Cancer Lett. 2008 Jul 18;266(1):53-9
references: 18362051
references: Biochem J. 2007 Jan 1;401(1):1-11
references: 17150040
references: Exp Physiol. 2006 Sep;91(5):807-19
references: 16857720
references: Cancer Res. 2007 May 15;67(10):4687-94
references: 17510395
references: Cancer Res. 1991 Feb 1;51(3):794-8
references: 1846317
references: Science. 2005 Jun 24;308(5730):1909-11
references: 15879174
references: Cancer Metastasis Rev. 2007 Jun;26(2):225-39
references: 17440684
references: Aging Cell. 2010 Aug;9(4):462-5
references: 20456297
references: Int J Cancer. 2009 Sep 15;125(6):1276-84
references: 19479998
references: Cell Cycle. 2010 Aug 15;9(16):3256-76
references: 20814239
references: J Biol Chem. 2006 Dec 1;281(48):36767-75
references: 17028194
references: Arch Biochem Biophys. 2002 Oct 15;406(2):173-82
references: 12361705
references: J Biol Chem. 2011 Feb 4;286(5):3717-28
references: 21059645
references: J Gerontol A Biol Sci Med Sci. 2008 Aug;63(8):813-22
references: 18772469
references: Expert Opin Drug Deliv. 2006 May;3(3):355-69
references: 16640496
references: Cancer Cell. 2008 Jan;13(1):58-68
references: 18167340
references: Mol Cell Biochem. 2004 Nov;266(1-2):37-56
references: 15646026
references: Clin Exp Metastasis. 2008;25(5):531-6
references: 18357506
references: Biochem Soc Trans. 2003 Dec;31(Pt 6):1441-4
references: 14641084
references: Transgenic Res. 2007 Apr;16(2):193-201
references: 17206489
references: Am J Pathol. 2003 Nov;163(5):2113-26
references: 14578209
references: Mol Cell Biol. 2000 Oct;20(19):7311-8
references: 10982848
references: Clin Cancer Res. 2007 Feb 1;13(3):789-94
references: 17289868
references: CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30
references: 16514137
references: Cancer Metastasis Rev. 2006 Sep;25(3):315-22
references: 16967326
references: Histol Histopathol. 1997 Apr;12(2):525-35
references: 9151141
references: Nat Rev Cancer. 2007 May;7(5):389-97
references: 17446858
references: Cancer Lett. 2001 Nov 28;173(2):115-25
references: 11597785
references: Annu Rev Pharmacol Toxicol. 2007;47:629-56
references: 17014364
references: Int J Cancer. 2002 Mar 1;98(1):148-54
references: 11857399
references: Breast Cancer Res. 2007;9(3):209
references: 17601353